PubMed · 11028307
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
I Takasaki, S Umemura. 2000. [Ca antagonists].. https://pubmed.ncbi.nlm.nih.gov/11028307/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Recently, Wu and Follmann developed summary measures to adjust for informative drop-out in longitudinal studies where drop-out depends on the underlying true value of the response. In this paper we evaluate these procedures in the common situation where drop-out depends on the observed responses. We also discuss various design and analysis strategies which minimize the bias obtained with this type of drop-out. Of particular interest is the use of multiple measurements of the response at each visit to reduce bias. These strategies are evaluated with a simulation study. The results are highlighted with applications to both a hypertensive and a respiratory disease clinical trial, where multiple measurements of the primary response were made for all participants at each visit.
Explore the source record for details and available documents.
Recent evidence suggests that regression of left ventricular hypertrophy (LVH) with antihypertensive therapy improves prognosis. The mechanism for this benefit is unknown but may be related to effects on myocardial performance. Midwall fractional shortening (mFS) is often depressed in patients with asymptomatic hypertension, is associated with LVH, and is a potent, independent predictor of outcome. We therefore examined whether antihypertensive therapy may improve midwall performance. mFS as well as conventional echocardiographic parameters were measured serially among 29 hypertensive persons during 6 months of drug therapy. Stress-adjusted and absolute midwall function improved by 10% and 11%, respectively (p <0.05), whereas no significant changes were detected in other measures of chamber function. Improvement in function was more pronounced in patients with concentrically remodeled ventricular geometry and in those who achieved greater reductions in left ventricular (LV) mass. Antihypertensive therapy and LV mass regression is associated with demonstrable improvements in cardiac performance when assessed using mFS. Determinations of mFS may have a promising role in identifying patients with early hypertensive heart disease, tracking responses to therapy, and in elucidating the potential beneficial effects associated with LV mass regression.